SERMs and gynecomastia in men

Tamoxifen and raloxifene are both used for breast tissue in men, and both are off-label for it. Unusually for this subject, there is real randomised evidence here — and it points clearly in one direction.

What the evidence shows

Findings are grouped by what kind of evidence each one is. That ordering is the point: a sentence from an FDA label and a sentence from a forum are not the same claim, and this page will not present them as though they were.

Regulator-reviewed (FDA label)

• Tamoxifen's FDA label covers breast cancer in men, but only breast cancer. Its entire dosing section is written for breast cancer indications, so every milligram figure used for gynecomastia is extrapolated from a different disease.

  Dose or parameter studied: 20 to 40 mg daily (label dose for breast cancer, not gynecomastia)

  Studied in: Women and men with breast cancer; women with DCIS or at high risk. No gynecomastia population is described anywhere on the label.

• Raloxifene has no approved use in men at all. Every indication on its label is restricted to postmenopausal women, and its 60 mg dose was established in postmenopausal women. A man taking raloxifene is outside the label on both indication and population, and carries a boxed warning for venous thromboembolism and death from stroke that was generated entirely in women.

  Dose or parameter studied: 60 mg orally once daily (postmenopausal-female dose; no male dose established)

  Studied in: Postmenopausal women with or at risk of osteoporosis, or at high risk of invasive breast cancer. Boxed warning derived from trials in postmenopausal women, including women with documented coronary heart disease.

Clinical trial evidence

• The only randomised dose-ranging study of tamoxifen for gynecomastia found a clean dose-response, with 20 mg/day clearly the best of five doses tested. This is the single strongest source for the widely-quoted 20 mg figure. Critically, the same trial showed the benefit did not persist: once tamoxifen was stopped and the hormonal driver continued for another 12 months, breast events returned across every arm including the 20 mg one. [1]

  Dose or parameter studied: Tamoxifen 20 mg/day orally for 12 months (compared against 1, 2.5, 5 and 10 mg/day and placebo)

  Studied in: 282 men with localised, locally advanced or biochemically recurrent prostate cancer taking bicalutamide 150 mg/day. Prophylaxis started with bicalutamide, i.e. before breast tissue developed - not treatment of tissue already present.

• In a double-blind placebo-controlled trial, tamoxifen 20 mg/day cut gynecomastia from 73% to 10% over 48 weeks, while the aromatase inhibitor anastrozole 1 mg/day did not work and caused nearly twice the adverse events. This is the core evidence that a SERM, not an AI, is the drug class with trial support in this setting. [2]

  Dose or parameter studied: Tamoxifen 20 mg/day for 48 weeks; comparator anastrozole 1 mg/day for 48 weeks

  Studied in: 114 men with localized, locally advanced or biochemically recurrent prostate cancer on bicalutamide 150 mg/day. Older men, androgen-receptor-blocked, with elevated testosterone and estradiol - a hormonal state unlike an AAS user's.

• The best evidence that tamoxifen can act on gynecomastia that has already appeared, rather than only preventing it, comes from a randomised trial where men who developed breast symptoms on bicalutamide were treated a median of 180 days (about 6 months) after onset and still improved significantly. Note the dose here was 10 mg/day, not 20 mg. [3]

  Dose or parameter studied: Tamoxifen 10 mg/day for 24 weeks (both as prophylaxis and as treatment started after symptom onset)

  Studied in: 151 men with prostate cancer on bicalutamide 150 mg/day; the treatment sub-randomisation covered 35 men who had already developed gynaecomastia or breast pain while the causative drug continued.

• A randomised trial directly comparing starting tamoxifen early versus waiting for symptoms found that treating established tissue leaves residual disease in about a quarter of men, and what remains is worse than what prevention leaves behind. This is the most direct trial evidence that timing changes the outcome, not just the speed of it. [4]

  Dose or parameter studied: Tamoxifen 10 mg/day started simultaneously with bicalutamide (prophylaxis) versus tamoxifen 20 mg/day started within 1 month of symptom onset (therapy); either given up to 1 year

  Studied in: 176 men with prostate cancer starting bicalutamide monotherapy. Gynecomastia assessed by self-reported visual analogue scale only - no ultrasound or calipers, so tissue size was not objectively measured.

• Intermittent or reduced-frequency tamoxifen dosing failed. A phase 3 trial testing 20 mg once weekly against 20 mg daily found weekly dosing more than doubled the gynecomastia rate and produced more severe tissue. Daily continuous dosing is what the evidence supports. [5]

  Dose or parameter studied: Tamoxifen 20 mg daily continuously versus tamoxifen 20 mg daily for 8 weeks then 20 mg weekly

  Studied in: 80 men with localised/locally advanced or biochemically recurrent prostate cancer on bicalutamide 150 mg/day, median follow-up 24.2 months. Gynaecomastia measured by ultrasonography, so tissue change here was objectively assessed.

• A 2025 meta-analysis of nine randomised trials quantified the effect: tamoxifen reduced breast events by 82%, radiotherapy by about half, and aromatase inhibition by nothing measurable. Anastrozole's repeated failure across trials is a specific caution against the common practice of reaching for an AI to reverse existing tissue. [6]

  Studied in: Men with prostate cancer receiving bicalutamide, pooled across nine randomised trials. No AAS or TRT users included.

• A GRADE-rated systematic review concluded the usable tamoxifen dose range in this indication is 10-20 mg daily, and that tamoxifen outperformed radiotherapy both as prevention and as treatment. This 10-20 mg range, drawn from prostate cancer trials, is the sourced basis for the doses circulating for gynecomastia generally. [7]

  Dose or parameter studied: Oral tamoxifen 10-20 mg daily

  Studied in: Men with prostate cancer on bicalutamide or flutamide, across eleven included studies. The review explicitly scopes itself to bicalutamide-induced gynecomastia.

• The 2026 SIAMS clinical practice guideline, developed under GRADE, draws the same line by tissue character rather than by a stopwatch: watchful waiting for recent-onset gynecomastia, drug therapy only in selected idiopathic or painful cases, and surgery once tissue is long-standing and fibrotic. It also states plainly that testosterone should be given only to men with proven hypogonadism - which speaks directly against using TRT to 'fix' gynecomastia in a eugonadal man. [12]

  Studied in: Adolescents and adults with gynecomastia of physiological, pharmacological, pathological, congenital and genetic origin. Guideline developed by a multidisciplinary expert panel using GRADE.

• Raloxifene is not endocrinologically inert in men. At 120 mg/day it significantly raised LH, FSH, total and free testosterone, and - importantly for anyone taking it to reduce estrogenic breast stimulation - estradiol rose 21% as well. PSA rose 17%. Its systemic hormonal effect in men is the opposite of what many users assume they are buying. [13]

  Dose or parameter studied: Raloxifene 120 mg/day for 3 months (twice the labelled 60 mg female dose)

  Studied in: 30 healthy men aged 60-70, double-blind placebo-controlled, bone and lipid endpoints. Not men with gynecomastia; no breast tissue endpoint was measured.

• Tamoxifen tolerability in men is reasonable across the published trials, with under 5% of men stopping for toxicity. But the same review states that rigorous long-term side-effect data in men simply do not exist - a gap that matters for anyone planning months of continuous use. [14]

  Studied in: Men prescribed tamoxifen for prostate cancer, male breast cancer, infertility, and idiopathic gynecomastia, pooled from RCTs and non-RCTs. Adverse event profile varied by which male population was treated.

• The AAS user's hormonal state is fundamentally different from the trial populations. AAS suppress LH, FSH and endogenous testosterone; after stopping, gonadotropins recover over 13-24 weeks but testosterone stays below baseline past 16 weeks. Gynecomastia is listed among the documented consequences. A SERM given during that recovery window is acting on a moving endocrine background that no gynecomastia trial has ever modelled. [15]

  Studied in: 3879 participants (1766 AAS users, 2113 non-users) across 33 studies of athletes and recreational users. This is the population the app serves, but these studies measured hormones and semen, not response of breast tissue to SERMs.

Off-label use of an approved drug

• The single most-cited claim that raloxifene beats tamoxifen for established tissue rests on one small retrospective chart review in adolescents, not a randomised trial in adults. It found raloxifene produced a greater-than-50% reduction in twice as many patients (86% vs 41%). The authors themselves flag that this may not be a true treatment effect. Anyone acting on 'raloxifene is stronger' should know it rests on 38 teenagers and no randomisation. [8]

  Studied in: 38 consecutive adolescents (mean age 14.6 years) with persistent pubertal gynecomastia at a paediatric endocrinology clinic. Retrospective chart review, non-randomised, no adults, no AAS or TRT users, no placebo arm.

• That same adolescent series is also the strongest published counterweight to a hard 'window' rule: the treated boys had carried gynecomastia for a mean of 28 months, well past any 6-or-12-month cutoff, and tissue still regressed on both drugs. Duration alone did not predict failure in this cohort. [8]

  Studied in: 38 adolescents with persistent pubertal gynecomastia of mean duration 28.3 months (SD 16.4). Pubertal gynecomastia is a self-limiting physiological process in many boys, which is itself a confounder the study design cannot exclude.

• In the population closest to a typical app reader - ordinary adult men with gynecomastia and no prostate cancer - a 10-year prospective cohort found 10 mg/day of tamoxifen produced complete resolution in about nine of ten men. This is the largest series in idiopathic gynecomastia, though it has no control arm and no randomisation. [9]

  Dose or parameter studied: Tamoxifen 10 mg daily orally

  Studied in: 81 men (mean age 42.8 years, SD 19.5) presenting to a UK breast clinic with primary/idiopathic gynecomastia, secondary causes excluded. 87.7% had breast pain. Not AAS or TRT users, and no comparison group.

• Tamoxifen-induced regression can reverse itself. In a comparative series where tamoxifen 20 mg/day outperformed danazol for complete resolution, five of the 23 tamoxifen-treated men subsequently had the breast mass come back - and every recurrence was in the tamoxifen group. Response is not the same as durable cure. [10]

  Dose or parameter studied: Tamoxifen 20 mg/day, continued until a static response was achieved (comparator danazol 400 mg/day)

  Studied in: 43 treated men with idiopathic gynecomastia at a Hong Kong breast clinic, median age 39.5 years, median symptom duration only 3 months (range 1-90). Retrospective, non-randomised.

• The reversal window is described in the literature qualitatively - by tissue phase, not by a number of months. Drug therapy is expected to work while the tissue is in its early proliferative phase, and to fail once gynecomastia is long-standing, at which point surgery is the realistic option. No retrieved source states a specific month cutoff as a measured threshold. [11]

  Studied in: Men receiving hormone therapy for prostate cancer, reviewed across large randomised placebo-controlled studies in which approximately 50% or more developed gynecomastia.

• SERM use for anabolic-steroid-related endocrine problems has no controlled evidence base. A review that set out to be a meta-analysis of AAS-induced hypogonadism management found that not one study met quality inclusion criteria, and could only offer expert opinion. Recommendations to use SERMs in AAS users are therefore consensus, not trial data. [16]

  Studied in: Men seeking treatment for symptomatic hypogonadism after non-prescribed AAS use - the closest published population to the app's readership, and the one where the evidence is thinnest.

• Even the observational picture of AAS-related gynecomastia is distorted by non-disclosure. When patients were re-interviewed after surgery, true AAS-associated prevalence was 39% versus the 4% recorded before the operation - a nearly tenfold under-report. Any published estimate of how AAS users respond to medical therapy is built on a base that under-counts them. [17]

  Studied in: All gynecomastia patients treated in a tertiary burns and plastic surgery department, June 2019 to June 2022, re-questioned 3 months post-surgery. Surgical cohort, not a medical-therapy cohort.

What the regulator approved

Where a drug on this page has a US label, this is what it was approved for and at what dose. Anything else is off-label — which is not the same as unsafe, but does mean no regulator has reviewed it for that use.

What nobody knows

These are the questions the literature does not answer. They are listed because on this subject the gaps are load-bearing: most of what circulates as settled practice sits in one of them.

• There is no randomised trial of tamoxifen or raloxifene for gynecomastia in AAS users or in men on TRT. A ClinicalTrials.gov search for gynecomastia returned only two registered tamoxifen trials, both in prostate cancer patients on bicalutamide and both sponsored by the bicalutamide manufacturer (NCT00233610, NCT00637871), and zero registered raloxifene trials for gynecomastia of any cause. Every dose and duration in this dossier is transferred from a different population.
• The studied population differs from the app's reader in a way that could cut either direction. Bicalutamide patients are older men whose androgen receptors are blocked while testosterone and estradiol both rise - the breast is unopposed because the receptor is jammed. An AAS user has supraphysiologic androgen with heavy aromatisation to estradiol, functioning receptors, and often a suppressed HPG axis. Whether a SERM performs the same way against these two mechanisms has never been tested.
• No trial defines a numeric reversal window. The 6-month and 12-month cutoffs circulating online were not found in any retrieved abstract as a measured threshold. What the sourced evidence actually supports is qualitative: Dobs (PMID 16217274) and the 2026 SIAMS guideline (PMID 42258023) both frame it as early/proliferative and responsive versus long-standing/fibrotic and surgical. The two data points that bracket it point in opposite directions - Perdona treated at a median 180 days from onset and still saw benefit, while Lawrence treated adolescents carrying tissue for a mean of 28 months and still saw regression.
• Raloxifene versus tamoxifen for established tissue in adult men has never been tested head-to-head. The entire basis for 'raloxifene is better' is one retrospective, non-randomised chart review of 38 adolescents (PMID 15238910) whose authors explicitly wrote that further study is required to determine whether this is truly a treatment effect. That study also does not report the milligram dose of either drug, so the raloxifene doses circulating in community sources have no source in the paper they are attributed to.
• No dose-ranging study of raloxifene exists in men for any breast endpoint. The 60 mg figure is the postmenopausal-osteoporosis dose. The only two controlled dosing studies in men used 60 mg (Doran, PMID 11697809, which found no significant change in bone turnover markers, sex steroids or lipids) and 120 mg (Duschek, PMID 15080785, which did move the HPG axis) - both for bone endpoints, neither measuring breast tissue. Whether 60 mg does anything at all to male breast tissue is genuinely unknown.
• The optimal tamoxifen dose for reversing existing tissue is unsettled. Kunath's systematic review (PMID 22925442) states outright that the optimal dose needs to be clarified. Fradet's dose-response trial tested prevention only; no comparable dose-ranging trial exists for treating tissue already present. Positive results exist at both 10 mg (Perdona, Mannu, Hanavadi) and 20 mg (Boccardo, Serretta, Ting), and Serretta's design deliberately used 10 mg to prevent and 20 mg to treat without ever testing whether that split is the right one.
• Durability after stopping is poorly characterised and the signal that exists is discouraging. Fradet found breast events returned across all arms including 20 mg once tamoxifen stopped and the driver continued; Ting saw recurrence in 5 of 23 tamoxifen-treated men. No study has followed AAS users after SERM discontinuation, so how much of any gain is held once the drug is stopped is unknown.
• Whether gynecomastia present when a cycle ends regresses on its own is unquantified. Christou (PMID 28258581) shows gonadotropins recover over 13-24 weeks while testosterone remains suppressed past 16 weeks, but no study tracks breast tissue across that recovery. This matters because it means the natural-history comparator for any self-administered SERM course is unknown - improvement may be partly or wholly spontaneous.
• Tamoxifen raises testosterone, LH, FSH, estradiol and SHBG in men (Saltzstein PMID 15685254; and raloxifene does the same per Duschek). How that HPG stimulation interacts with concurrent exogenous androgens, hCG, or an aromatase inhibitor has not been studied in any trial. Stacking assumptions here are unsupported.
• Long-term safety in men is not quantified. Tamoxifen's boxed warning - uterine malignancy, stroke, pulmonary embolism - was generated entirely in women in the DCIS and risk-reduction setting and does not transfer numerically to men. Wibowo (PMID 27152880) states directly that long-term studies rigorously documenting tamoxifen's side-effect profile in men are lacking. Raloxifene's boxed warning for VTE and death from stroke likewise comes from postmenopausal women, including a trial in women with coronary heart disease; there is no male safety dataset at gynecomastia-relevant durations. VTE risk in a young male AAS user, who may already have elevated haematocrit, is entirely unmodelled.
• Aromatase inhibitors failed repeatedly in the only controlled setting where they were tested (Boccardo PMID 15681525; Spagnolo PMID 40244528 found no significant benefit for anastrozole, alongside nearly double the adverse-event rate in Boccardo). Despite this they remain common in community practice for established tissue. No retrieved trial supports that use.
• Objective measurement is inconsistent across the evidence base. Serretta used a self-reported visual analogue scale with explicitly no ultrasonography or calipers; Bedognetti used ultrasound; Fagerlund's broader systematic review (PMID 26051284) graded the non-prostate-cancer gynecomastia literature as high risk of bias and very low quality of evidence under GRADE. Reported response rates are therefore not directly comparable between studies.
• Nothing in this evidence base addresses distinguishing glandular gynecomastia from pseudogynecomastia or from male breast cancer before starting a drug, which is the step every guideline places ahead of pharmacotherapy. Self-treatment without that assessment risks delaying diagnosis of a malignancy that the SERM would partially mask.

Sources

Every identifier below was checked to resolve to a real record before publication. Citations retrieved from PubMed and DailyMed.

1. European Urology (2007) — PubMed 17270340 At 6 and 12 mo, tamoxifen decreased the incidence of breast events in a dose-dependent manner, with breast events observed in 86.2%, 60.0%, 55.3%, 23.5%, and 8.8% of patients receiving tamoxifen 1, 2.5, 5, 10, and 20 mg, respectively, compared with 96.7% of pa
2. Journal of Clinical Oncology (2005) — PubMed 15681525 Gynecomastia developed in 73% of patients in the bicalutamide group, 10% of patients in the bicalutamide-tamoxifen group, and 51% of patients in the bicalutamide-anastrozole group (P < .001); breast pain developed in 39%, 6%, and 27% of patients, respectively
3. The Lancet Oncology (2005) — PubMed 15863377 51 patients were randomly assigned to 150 mg bicalutamide per day, 50 patients to 150 mg bicalutamide per day and to 10 mg tamoxifen per day for 24 weeks, and 50 patients to 150 mg bicalutamide per day and radiotherapy (one 12-Gy fraction on the day of startin
4. Clinical Genitourinary Cancer (2012) — PubMed 22502790 One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs. TAM 10 mg daily starting simultaneously with bicaluta
5. European Urology (2009) — PubMed 19481335 Gynaecomastia developed in 31.7% of patients in the daily group and in 74.4% of patients in the weekly group (p<0.0001), and it was more severe in patients who switched to weekly tamoxifen (p=0.001). Mastalgia occurred in 12.2% and 46.1% of patients, respectiv
6. Journal of Endocrinological Investigation (2025) — PubMed 40244528 Tamoxifen significantly reduced the risk of breast events by 82% (RR: 0.18, 95% CI: 0.08-0.38 for gynecomastia and RR: 0.18, 95% CI: 0.07-0.43 for breast pain). Radiotherapy reduced gynecomastia risk by 52% (RR: 0.48, 95% CI: 0.38-0.59) and breast pain by 34%
7. PLoS One (2015) — PubMed 26308532 Bicalutamide-induced gynecomastia and/or mastodynia can effectively be managed by oral tamoxifen (10-20 mg daily) or radiotherapy without relevant side effects. Prophylaxis or therapeutic treatment with tamoxifen results to be more effective than radiotherapy.
8. The Journal of Pediatrics (2004) — PubMed 15238910 Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with
9. The Breast Journal (2018) — PubMed 30079473 We undertook a prospective cohort study of all male patients who presented to our breast clinic, were diagnosed with primary gynecomastia, and were treated with a trial of tamoxifen 10 mg daily therapy, over a 10-year period from October 2004 to October 2015.
10. The American Surgeon (2000) — PubMed 10651345 Medical treatment with either tamoxifen (20 mg/d) or danazol (400 mg/d) was offered and continued until a static response was achieved. ... Complete resolution of the gynecomastia was recorded in 18 patients (78.2%) treated with tamoxifen, whereas only 8 patie
11. The Journal of Urology (2005) — PubMed 16217274 Tamoxifen may also mitigate or resolve gynecomastia during its early or proliferative phase. In severe long-standing gynecomastia surgery is warranted since medical therapies are less likely to succeed.
12. Journal of Endocrinological Investigation (2026) — PubMed 42258023 Observation is recommended for physiological or recent-onset cases. Pharmacological therapy may be considered in selected idiopathic or painful forms, whereas testosterone replacement should be restricted to men with proven hypogonadism. Surgery is indicated f
13. European Journal of Endocrinology (2004) — PubMed 15080785 Thirty healthy men aged 60-70 years randomly received raloxifene 120 mg/day (n=15) or placebo (n=15) for 3 months. ... Raloxifene significantly increased serum concentrations of LH and FSH (by 29% and 21%), total testosterone (20%), free testosterone (16%) and
14. Andrology (2016) — PubMed 27152880 Tamoxifen is an off-label option to treat men for breast cancer, infertility, and idiopathic gynecomastia. ... Less than 5% of men withdrew from tamoxifen therapy because of toxicity. This suggests that for most men, tamoxifen is well-tolerated. ... Long-term
15. Sports Medicine (2017) — PubMed 28258581 During AAS intake, significant reductions in luteinizing hormone [weighted mean difference (WMD) -3.37 IU/L, 95% confidence interval (CI) -5.05 to -1.70, p < 0.001], follicle-stimulating hormone (WMD -1.73 IU/L, 95% CI -2.67 to -0.79, p < 0.001), and endogenou
16. Fertility and Sterility (2014) — PubMed 24636400 Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria. ... Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement
17. Indian Journal of Plastic Surgery (2023) — PubMed 37705825 Real prevalence of AAS-associated gynecomastia (39.19%) was much higher than that recorded in preoperative period (4.05%). Also, AAS users were having higher body mass index and a greater proportion of patients were bodybuilders. Patients with high body mass i
18. Tamoxifen citrate (oral tablets) — US Prescribing Information (DailyMed) Approved indication: Breast cancer only: metastatic breast cancer in women and men; adjuvant treatment of node-positive and node-negative breast cancer in women; ductal carcinoma in situ; and reduction of breast cancer in
19. Raloxifene hydrochloride (oral tablets) — US Prescribing Information (DailyMed) Approved indication: Treatment and prevention of osteoporosis in postmenopausal women; reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk. Every approved indication is re

/* First touch: store whatever brought them here before anything overwrites it. */ (function () { try { if (localStorage.getItem('tl_attr')) return; var p = new URLSearchParams(location.search); var fields = ['utm_source','utm_medium','utm_campaign','utm_content','utm_term','ref','rdt_cid','fbclid','gclid']; var found = {}; fields.forEach(function (f) { var v = p.get(f); if (v) found[f] = String(v).slice(0, 80); }); if (Object.keys(found).length) { found.landedAt = new Date().toISOString(); found.landingPage = location.pathname; localStorage.setItem('tl_attr', JSON.stringify(found)); } } catch (e) {} })();